September 25, 2013
PROTIDE PHARMACEUTICALS, INC. INTRODUCES COLD STORAGE CELL SOLUTION
Lake Zurich IL — Protide Pharmaceuticals , Inc. (“Protide”) announced today the introduction of 2-8 CELLsius*, a solution for improving the physiological condition of cells during processing, cold storage, pre and post cryopreservation and transportation.
“We developed this solution to improve targeted cells and tissue including but not limited to stem cells, islet cells, cartilage, bone and hair,”  said Milo R. Polovina, Chairman and CEO.  “The 2-8 CELLsius* technology is a prominent addition to our cell therapy/regenerative medicine program.”
2-8 CELLsius* can be used with other proprietary Protide solutions such as: TCH*, Cellvation*, pZerve*, Stemsol* and MiCord*.
Protide is a fully integrated organization devoted to the discovery, development and commercialization of technologies and processes in clinical cell therapy, regenerative medicine, transfusion medicine, cell engineering and transplantation.

*2-8 CELLsius, TCH, Cellvation, pZerve, Stemsol, and MiCord are registered trademarks of Protide Pharmaceuticals, Inc.

March 7, 2012
PROTIDE PHARMACEUTICALS, INC. ANNOUCES AHEPA PARTICIPATION
Lake Zurich IL — Protide Pharmaceuticals employees to participate in AHEPA basketball tournament March 7-11 2012 in Chicago, IL. The AHEPA organization’s purpose is to encourage people of Greek and Eastern European descent to register with national and international bone marrow registries. Currently those groups are underrepresented in registries.

February 1, 2012
PROTIDE PHARMACEUTICALS, INC. RECEIVES NOTICE OF NEW TRADEMARK FOR DMSO/DEXTRAN CRYOPRESERVATIVE
Lake Zurich IL — Milo R. Polovina, President and CEO announced today that Protide has received notice of a new trademark for it’s stem cell cryopreservative, MiCord™. The DMSO/Dextran 55%,w/v 5% w/v cryopreservative has been used worldwide for over 16 years.

JANUARY 1, 2012
PROTIDE PHARMACEUTICALS, INC. RE-INTRODUCES BALANCED SALT SOLUTIONS TO CATALOG
Lake Zurich IL — Milo R. Polovina, President and CEO announced today that Protide has restarted manufacturing Hank’s Balanced Salt Solution and Phosphate Buffered Saline Solutions for cell processing. Protide has over 25 years’ experience manufacturing cell processing solutions for laboratory use. Customers requested access to our high quality solutions again while ordering from a singe source.

NOVEMBER 1, 2011
PROTIDE PHARMACEUTICALS , INC.SIGNS NEW DISTRIBUTOR
Lake Zurich IL– Milo R. Polovina, President and CEO announced today that Protide has entered into a distribution agreement with Cedarlane® Labs of Canada to market and distribute Protide’s cryopreservation media and serum replacement products. This agreement will bolster Protide’s product presence in Canada, further adding to an impressive distribution network including Funakoshi (Japan), MP Biomedicals, Sigma Aldrich, MP Biomedicals, Takara(Japan). CedarlaneR Labs focuses on products for Immunology, Molecular Biology, Cell Biology and Neurobiology.

March 27, 2011
PROTIDE PHARMACEUTICALS, INC. EMPLOYEES REGISTER WITH NMDP
Employees, friends and family of Protide Pharmaceuticals and Celox Laboratories register with the National Marrow Donor Program (NMDP). President and CEO Milo R. Polovina commented “we are pleased to support this important program and urge the participation of diverse ethnic backgrounds.”

MARCH 8, 2004
PROTIDE PHARMACEUTICALS, INC. ANNOUNCES FORM 15 FILING
ST. PAUL, MN–Protide Pharmaceuticals, Inc. (OTCBB:PPMD.OB) is announcing the filing of a Form 15 with the Securities and Exchange Commission (SEC) to terminate registration of Protide Pharmaceuticals’ common stock under the Securities Exchange Act of 1934.